Deal overview
| Target | DAIICHI SANKYO (CERTAIN RIGHTS TO TRASTUZUMAB DERUXTECAN) |
|---|---|
| Bidder | ASTRAZENECA PLC |
| Price | £60.00 Full version or £25.00 Light version |
| Publication Date | Mar 28, 2019 |
| Abstract | On 28 March 2019[+], it was announced that the UK quoted pharmaceuticals group AstraZeneca Plc, had entered into a global development and commercialisation collaboration agreement with the Japanese quoted pharmaceuticals group Daiichi Sankyo Company, Limited ("Daiichi Sankyo") for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate ("ADC") and potential ... |
| Number of pages (Full version) | 6 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
